https://www.selleckchem.com/pr....oducts/gw806742x.htm
Median follow-up period was 13 months (range1-43). Overall survival in patients with CR/PR was significantly better than in those with SD/PD (p = 0.006); with 3-year survival rates of 45 % (8/17) and 0% (0/25), respectively. BAE using NBCA has potential promise for shrinking hilar and/or mediastinal tumors that are refractory to chemotherapy or chemoradiotherapy, and may also improve overall survival in patients who respond. BAE using NBCA has potential promise for shrinking hilar and/or mediastinal tumors that are refractory to chemo
Like
Comment
Share
